Mixed infection by Clostridium difficile in an in vitro model of the human gut

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 5, 2013, Pages 1139-1143

  Baines, Simon D ^a   Crowther, Grace S ^b   Todhunter, Sharie L ^b   Freeman, Jane ^c   Chilton, Caroline H ^b   Fawley, Warren N ^c   Wilcox, Mark H ^b,c  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Ceftriaxone; Epidemiology; Resistance; Spores

Indexed keywords

CEFTRIAXONE; CLINDAMYCIN; CYTOTOXIN; METRONIDAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL REPRODUCTION; BACTERIAL STRAIN; BACTERIAL VIABILITY; BIFIDOBACTERIUM; CHEMOSTAT; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONCENTRATION RESPONSE; ENTEROCOCCUS; IN VITRO STUDY; INTESTINE; INTESTINE FLORA; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; NONHUMAN; POLYMERASE CHAIN REACTION; RIBOTYPING; SPORE GERMINATION;

ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BIFIDOBACTERIUM; CEFTRIAXONE; CLOSTRIDIUM DIFFICILE; ENTEROCOCCUS; GASTROINTESTINAL TRACT; HUMANS; MICROBIAL VIABILITY; MODELS, THEORETICAL; SPORES, BACTERIAL;

EID: 84877158163     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks529     Document Type: Article

References (20)

1. McGlone SM, Bailey RR, Zimmer SM et al. The economic burden of Clostridium difficile. Clin Microbiol Infect 2012; 18: 282-9.
2. Wilcox MH, Fawley WN, Settle CD et al. Recurrence of symptoms in Clostridium difficile infection-relapse or reinfection? J Hosp Infect 1998; 38: 93-100.
3. Tanner HE, Hardy KJ, Hawkey PM. Coexistence of multiple multilocus variable tandem-number tandem-repeat analysis subtypes of Clostridium difficile PCR ribotype 027 strains within fecal specimens. J Clin Microbiol 2010; 48: 985-7.
4. Eyre DW, Walker AS, Griffiths D et al. Clostridium difficile mixed infection and reinfection. J Clin Microbiol 2012; 50: 142-4.
5. Baines SD, Freeman J, Wilcox MH. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother 2005; 55: 974-82.
6. Baines SD, Freeman J, Wilcox MH. Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. Antimicrob Agents Chemother 2009; 53: 2202-4.
7. Best EL, Freeman J, Wilcox MH. Models for the study of Clostridium difficile infection. Gut Microbes 2012; 3: 145-67.
8. Fawley WN, Freeman J, Wilcox MH. Evidence to support the existence of subtypes within the UK epidemic Clostridium difficile strain (PCR ribotype 1). J Hosp Infect 2003; 54: 74-7.
9. Baines SD, O'Connor R, Freeman J et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62: 1046-52.
10. Fawley WN, Freeman J, Smith C et al. Use of highly discriminatory fingerprinting to analyze clusters of Clostridium difficile infection cases due to epidemic ribotype 027 strains. J Clin Microbiol 2008; 46: 954-60.
11. Macfarlane GT, Macfarlane S, Gibson GR. Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microb Ecol 1998; 35: 180-7.
12. Freeman J, Baines SD, Saxton K et al. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 2007; 60: 83-91.
13. Freeman J, O'Neill FJ, Wilcox MH. Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J Antimicrob Chemother 2003; 52: 96-102.
14. Pletz MW, Rau M, Bulitta J et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother 2004; 48: 3765-2.
15. Settle CD, Wilcox MH, Fawley WN et al. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther 1998; 12: 1217-233.
16. Crowther GS, Baines SD, Todhunter SL et al. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. J Antimicrob Chemother 2013; 68: 168-76.
17. Bush K, Sykes RB. Methodology for the study of b-lactamases. Antimicrob Agents Chemother 1984; 16: 6-11.
18. Welling GW, Holtrop A, Slootmaker-van der Meulen C et al. Inactivation of ceftriaxone by faecal enzyme preparations during ceftriaxone treatment. J Antimicrob Chemother 1992; 30: 234-6.
19. Akerlund T, Svenungsson B, Lagergren A et al. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficileassociated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol 2006; 44: 53-8.
20. Eyre DW, Golubchik T, Gordon NC et al. A pilot study of rapid benchtop sequencing of Staphylococcus aureus and Clostridium difficile for outbreak detection and surveillance. BMJ Open 2012; 2: e001124.